3I4B | pdb_00003i4b

Crystal structure of GSK3b in complex with a pyrimidylpyrrole inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 
    0.222 (Depositor), 0.210 (DCC) 
  • R-Value Work: 
    0.179 (Depositor), 0.172 (DCC) 
  • R-Value Observed: 
    0.181 (Depositor) 

Starting Model: other
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 3I4B

Ligand Structure Quality Assessment 


This is version 1.5 of the entry. See complete history

Literature

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

Aronov, A.M.Tang, Q.Martinez-Botella, G.Bemis, G.W.Cao, J.Chen, G.Ewing, N.P.Ford, P.J.Germann, U.A.Green, J.Hale, M.R.Jacobs, M.Janetka, J.W.Maltais, F.Markland, W.Namchuk, M.N.Nanthakumar, S.Poondru, S.Straub, J.ter Haar, E.Xie, X.

(2009) J Med Chem 52: 6362-6368

  • DOI: https://doi.org/10.1021/jm900630q
  • Primary Citation Related Structures: 
    3I4B, 3I5Z, 3I60

  • PubMed Abstract: 

    The Ras/Raf/MEK/ERK signal transduction, an oncogenic pathway implicated in a variety of human cancers, is a key target in anticancer drug design. A novel series of pyrimidylpyrrole ERK inhibitors has been identified. Discovery of a conformational change for lead compound 2, when bound to ERK2 relative to antitarget GSK3, enabled structure-guided selectivity optimization, which led to the discovery of 11e, a potent, selective, and orally bioavailable inhibitor of ERK.


  • Organizational Affiliation
    • Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139-4242, USA. alex_aronov@vrtx.com

Macromolecule Content 

  • Total Structure Weight: 93.06 kDa 
  • Atom Count: 6,342 
  • Modeled Residue Count: 706 
  • Deposited Residue Count: 828 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Glycogen synthase kinase-3 beta
A, B
414Homo sapiensMutation(s): 0 
Gene Names: GSK3B
EC: 2.7.11.26 (PDB Primary Data), 2.7.11.1 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P49841 (Homo sapiens)
Explore P49841 
Go to UniProtKB:  P49841
PHAROS:  P49841
GTEx:  ENSG00000082701 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP49841
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Z48

Query on Z48



Download:Ideal Coordinates CCD File
C [auth A],
D [auth B]
N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(phenylamino)pyrimidin-4-yl]-1H-pyrrole-2-carboxamide
C24 H23 N5 O2
PFHKAGAZRDERTK-OAQYLSRUSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free:  0.222 (Depositor), 0.210 (DCC) 
  • R-Value Work:  0.179 (Depositor), 0.172 (DCC) 
  • R-Value Observed: 0.181 (Depositor) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 82.75α = 90
b = 86.1β = 90
c = 178.29γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
BUSTER-TNTrefinement
PDB_EXTRACTdata extraction
CrystalCleardata collection
AMoREphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

  • Released Date: 2010-01-12 
  • Deposition Author(s): Ter Haar, E.

Revision History  (Full details and data files)

  • Version 1.0: 2010-01-12
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2017-11-01
    Changes: Refinement description
  • Version 1.3: 2018-04-04
    Changes: Data collection
  • Version 1.4: 2024-02-21
    Changes: Data collection, Database references, Derived calculations
  • Version 1.5: 2024-04-03
    Changes: Refinement description